HOME >> MEDICINE >> NEWS
Zengen reports positive phase I/II trial results of its peptide molecule for vaginal yeast infection

(May 25, 2004) Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection. The open label, non-randomized study was designed to evaluate the safety, tolerability and pharmacokinetics of CZEN-002 in patients with VVC.

The majority of subjects in the study reported evidence of efficacy as determined by potassium hydroxide (KOH) tests and mycological cultures - 88.2 percent and 87.5 percent, respectively. A total of 20 female patients with VVC were enrolled and treated in the trial, and 17 completed the study. KOH testing and mycological cultures indicated that CZEN-002 is active and that five days of treatment provided positive evidence of anti-infective efficacy. CZEN-002 appeared safe and well-tolerated with no severe adverse reactions. In 100 percent of the plasma samples evaluated, concentrations of CZEN 002 were either not detected or were below the limit of quantitation.

"This trial clearly established the efficacy of CZEN-002," said William Smith, M.D., F.A.C.C., lead study investigator and associate professor, clinical medicine, at Tulane University School of Medicine and Louisiana State University Medical Center. "The encouraging results provide hope that this compound may become a new treatment option for the millions of women diagnosed each year with VVC."

The primary objective of the study was to evaluate the safety and tolerability of vaginally administered CZEN-002. A secondary objective was to assess the systemic absorption of CZEN-002 as determined by the plasma concentrations of the molecule through 21 days following dosing. The CZEN 002 was delivered to the 20 patients in a vaginal gel specifically designed for the purpose of the study.

"This clinical trial marks a major milestone for Zengen," said James M. Lipton, Ph.D., chief scientific officer of Zengen. "Our peptide appears to
'"/>

Contact: Cattaliya Snider
sniderc@ruderfinn.com
310-479-9929
Zengen
25-May-2004


Page: 1 2 3

Related medicine news :

1. Zengens new study reviews novel approach to control inflammation using melanocortin receptors
2. Lead in the environment causes violent crime, reports University of Pittsburgh researcher at AAAS
3. Study reports women dont experience undue pain, anxiety during mammography screening
4. Risks from labor after prior cesarean delivery low, study reports
5. Federal forum reports Americans aging well, but gaps remain
6. Early reports of thrombosis after insertion of drug-eluting stents
7. Study reports genetic susceptibility to alcoholism in NMDA receptor
8. Parents can provide accurate reports of their childrens ADHD symptoms
9. UCI Tobacco research center reports why teens are most vulnerable to smoking addiction
10. MIT reports new insights in visual recognition
11. Study reports improved method to identify fetal DNA in maternal blood samples

Post Your Comments:
(Date:11/27/2014)... November 27, 2014 "As a nurse ... side effects of urinary incontinence," said an inventor from ... developed this specialized accessory to prevent leakage and keep ... to absorb urine leakage. This prevents stains on pants, ... embarrassment. The pad ensures that the individual has time ...
(Date:11/27/2014)... News) -- Thanksgiving meals can pose a challenge for ... expert says. Many traditional Thanksgiving dishes -- such ... are gluten-free, but "when it comes to pies, stuffing, ... Dr. Anca Safta, director of the Gluten and Allergic ... in North Carolina, said in a center news release. ...
(Date:11/27/2014)... Tylenol lawsuits ( http://www.tylenollawsuitcenter.com/ ) filed ... the medication are continuing to move forward in Pennsylvania ... to a status conference in December, Bernstein Liebhard LLP ... earlier this year, a conference in the Tylenol proceeding ... Items likely to be discussed at the meeting include ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Developers and plugin ... new plugin entitled ProPip, taking FCPX to the next level. ... effect with a few clicks of a mouse,” said Christina ... saver that our users will appreciate.” , With ProPip users ... leaving the possibilities truly endless. ProPip is great for commentaries, ...
(Date:11/27/2014)... children to help with chores while they are home from ... boosts self-esteem, and above all, helps parents maintain a somewhat ... how do you encourage your children to want to help? ... Child Development Journal, there is. The study found that adults’ ... to lend a hand. , The study found that ...
Breaking Medicine News(10 mins):Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3
(Date:11/26/2014)... ELMSFORD, N.Y. , Nov. 26, 2014  BioScrip ® , ... M. Smith , President and Chief Executive Officer, will present at ... follows: , , , Date: , , , ... , , 2:50 p.m. EST , , , , Location: ... About BioScrip, Inc. ...
(Date:11/26/2014)... 2014 The medical magnetic resonance imaging ... 4%, with world market revenues for 2013 at ... other types of medical imaging have led to ... medical conditions in children and adults, each imaging ... Medical Imaging Markets , analyzes the current ...
(Date:11/26/2014)... Nov. 25, 2014 Reinforcing its commitment to ... (NYSE: PHG AEX: PHIA) today announced ... (FDA) for its IQon Spectral CT , presenting ... kind technology adds a new dimension to Computed Tomography ... to characterize structures based on their material content within ...
Breaking Medicine Technology:Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3
Cached News: